Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
P Domingo, I Mur, GM Mateo, M del Mar Gutierrez… - Jama, 2021 - jamanetwork.com
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
[HTML][HTML] Direct oral anticoagulant plasma levels' striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona …
S Testa, P Prandoni, O Paoletti, R Morandini… - Journal of Thrombosis …, 2020 - Elsevier
Background Antiviral drugs are administered in patients with severe COVID‐19 respiratory
syndrome, including those treated with direct oral anticoagulants (DOACs). Concomitant …
syndrome, including those treated with direct oral anticoagulants (DOACs). Concomitant …
Colchicine is safe though ineffective in the treatment of severe COVID-19: a randomized clinical trial (COLCHIVID)
A Absalón-Aguilar, M Rull-Gabayet… - Journal of General …, 2022 - Springer
Background Colchicine is an available, safe, and effective anti-inflammatory drug and has
been suggested as a COVID-19 treatment, but its usefulness in hospitalized severe COVID …
been suggested as a COVID-19 treatment, but its usefulness in hospitalized severe COVID …
Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID‐19
JM Rivera‐Caravaca, IJ Núñez‐Gil… - European Journal of …, 2021 - Wiley Online Library
Background The coronavirus disease 2019 (COVID‐19) shows high morbidity and mortality,
particularly in patients with concomitant cardiovascular diseases. Some of these patients are …
particularly in patients with concomitant cardiovascular diseases. Some of these patients are …
[HTML][HTML] Treating COVID-19 with colchicine in community healthcare setting
E Della-Torre, F Della-Torre, M Kusanovic… - Clinical Immunology …, 2020 - ncbi.nlm.nih.gov
In late February 2020 the Lombardy region (Italy) was dramatically hit by a new infectious
coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome …
coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome …
Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients-mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19–Repurposed Drugs …
S Kulkarni, M Fisk, M Kostapanos, E Banham-Hall… - Trials, 2020 - Springer
Objectives To determine if a specific immunomodulatory intervention reduces progression of
COVID-19-related disease to organ failure or death, compared to standard of care (SoC) …
COVID-19-related disease to organ failure or death, compared to standard of care (SoC) …
Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial
Importance Acutely ill inpatients with COVID-19 typically receive antithrombotic therapy,
although the risks and benefits of this intervention among outpatients with COVID-19 have …
although the risks and benefits of this intervention among outpatients with COVID-19 have …
Colchicine use in patients with COVID-19: A systematic review and meta-analysis
Introduction Colchicine may inhibit inflammasome signaling and reduce proinflammatory
cytokines, a purported mechanism of COVID-19 pneumonia. The aim of this systematic …
cytokines, a purported mechanism of COVID-19 pneumonia. The aim of this systematic …
Impact of colchicine on mortality and morbidity in COVID-19: a systematic review
Introduction Colchicine, because of its anti-inflammatory and possible anti-viral properties,
has been proposed as potential therapeutic option for COVID-19. The role of colchicine to …
has been proposed as potential therapeutic option for COVID-19. The role of colchicine to …
Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis
Globally, there have been close to 130 million reported cases of coronavirus disease 2019
(COVID-19) as of 2nd April 2021, with 2.8 million deaths documented [1]. In order to reduce …
(COVID-19) as of 2nd April 2021, with 2.8 million deaths documented [1]. In order to reduce …